Search hospitals > Kentucky > Lexington
University of Kentucky
Claim this profileLexington, Kentucky 40504
Global Leader in Alzheimer's Disease
Global Leader in Stroke
Conducts research for Cystic Fibrosis
Conducts research for Leukemia
Conducts research for Lung Cancer
674 reported clinical trials
71 medical researchers
Summary
University of Kentucky is a medical facility located in Lexington, Kentucky. This center is recognized for care of Alzheimer's Disease, Stroke, Cystic Fibrosis, Leukemia, Lung Cancer and other specialties. University of Kentucky is involved with conducting 674 clinical trials across 896 conditions. There are 71 research doctors associated with this hospital, such as Lars Wagner, MD, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.Top PIs
Lars Wagner, MDDuke University Medical Center7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
51 reported clinical trials
98 drugs studied
Susanne Arnold, MDUniversity of Kentucky/Markey Cancer Center1 year of reported clinical research
Expert in Cancer
Expert in Non-Small Cell Lung Cancer
34 reported clinical trials
70 drugs studied
John Villano, MD, PhDUniversity of Kentucky/Markey Cancer Center5 years of reported clinical research
Studies Cancer
Studies Brain Tumor
20 reported clinical trials
36 drugs studied
Zin W. MyintUniversity of Kentucky/Markey Cancer Center3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
12 reported clinical trials
26 drugs studied
Clinical Trials running at University of Kentucky
Surgical Site Infection
Bleeding
Ovarian Cancer
Breast Cancer
Broken Bones
Osteomyelitis
Non-Small Cell Lung Cancer
Bladder Cancer
Fallopian Tube Cancer
Follicular Lymphoma
Antibiotic Care
for Fractures
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Recruiting4 awards Phase 315 criteria
Tobramycin Injection
for Open Fractures
The goal of open extremity fracture (OEF) treatment is to promote fracture healing and restore function while preventing the development of infection. This is achieved through systematic and timely wound debridement and irrigation, fracture stabilization, tetanus prophylaxis, systemic and local antimicrobial therapy, and judicious timing of wound closure based on cleanliness. Early prophylactic systemic antibiotics lower infection rates in open fractures but have limitations of achieving adequate concentration at the hypoperfused wound area. OEF wounds are frequently poor in vasculature secondary to the soft tissue injury, hence adequate concentration of antibiotic cannot permeate to the tissue at risk. If systemic antibiotic concentrations are increased to achieve minimum inhibitory concentration (MIC) for pathogens at the wound, there is heightened concern for systemic drug toxicity. In sharp contrast, locally administered antibiotics achieve high drug concentration directly within the wound cavity with minimal systemic side effects. Local antibiotic therapy has shown to reduce rates of open fracture wound infection. With the serious implications of postoperative infections in OEF, it is imperative that all measures including further use of prophylactic local antibiotics be considered to prevent fracture-related infection (FRI). The overarching hypothesis for this project is that a novel synergistic combination of local aqueous tobramycin plus perioperative weight-based IV cephalosporin antibiotic prophylaxis will reduce the rate of FRI one year after OEF surgery. This in turn will improve OEF patient outcomes, decreasing morbidity and return to the operating room (OR) without any adverse effect on fracture healing. Regardless of the treatment group, bacterial speciation will be determined for patients that do develop FRI to help guide future treatment. The goal is to improve the clinical outcome and recovery of the population that sustains an OEF by decreasing the rate of FRI and fracture nonunions while concurrently educating on bacterial speciation and resistance.
Recruiting2 awards Phase 3
Topical Antibiotics
for Surgical Site Infection
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kentucky?
University of Kentucky is a medical facility located in Lexington, Kentucky. This center is recognized for care of Alzheimer's Disease, Stroke, Cystic Fibrosis, Leukemia, Lung Cancer and other specialties. University of Kentucky is involved with conducting 674 clinical trials across 896 conditions. There are 71 research doctors associated with this hospital, such as Lars Wagner, MD, Susanne Arnold, MD, John Villano, MD, PhD, and Zin W. Myint.
Where is University of Kentucky located?
The University of Kentucky Hospital is situated on the main campus in Lexington, Kentucky, at 800 Rose Street. It is accessible via Exit 115 from I-64, with clear signage directing to the hospital.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Kentucky Hospital:
- Contact the Financial Counseling department at 859-323-9898 for the Financial Assistance Program. This program aids uninsured or underinsured patients who receive emergency or medically necessary services and face financial hardship due to medical expenses.
- To apply, complete the Financial Assistance application form and submit household income information.
- For insurance inquiries, reach out to UK Health Connection at 859-257-1000 or 800-333-8874.
What insurance does University of Kentucky accept?
The University of Kentucky Hospital accepts a wide range of insurance plans, such as Aetna/U.S. HealthCare, Anthem Blue Cross and Blue Shield, Baptist Health Plan, CIGNA, Humana, UK-HMO, and United HealthCare. It is crucial to verify your insurance details with your doctor or clinic before your visit. In-network policies include Aetna Medicare Advantage, Anthem Medicaid, Anthem Medicare Advantage, CareSource Advantage (Medicare), Aetna Better Health Medicaid, and Humana Healthy Horizons.
What awards or recognition has University of Kentucky received?
The University of Kentucky Albert B. Chandler Hospital at UK HealthCare is the No. 1 hospital in Kentucky, as recognized by the U.S. News & World Report for eight consecutive years. It boasts three specialties ranked in the top 50 nationally: Cancer Care (#44), Ear, Nose & Throat (#49, tied), and OB/GYN (#40). Additionally, it has earned the prestigious Magnet designation for nursing excellence from the American Nurses Credentialing Center.